CDKN2A and familial pancreatic carcinoma: Whole genome sequencing of such familial pancreatic cancer (FPC) patients has recently elucidated the heterogeneous mutational landscape and outlined the importance of mutations in susceptibility genes like ATM, BRCA2, and CDKN2A (cyclin-dependent kinase inhibitor 2A) [2,3,4,5].